BLeeding Events and Maintenance DoSe of PraSugrel
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 195 participants.
Also called NCT01790854
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 195 participants
- Sponsor
- David Antoniucci
- Registry
-
NCT01790854
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Terminated
Technical summary
Registry record NCT01790854. Randomized; no masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2014-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BLeeding Events and Maintenance DoSe of PraSugrel
- Acronym
- BLESS
- Condition
- Adverse Reaction to Antiplatelet Agent
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Prasugrel dose 5 mg/day
- Intervention (Drug)
- Prasugrel dose 10 mg/day
- Lead sponsor
- David Antoniucci
- Collaborator
- A.R. CARD Onlus Foundation
Record details
- Record id
cardio:ct-nct01790854- Content hash
372fafb219697d3b53898c79635eca136d05454fd6892c3683ea4309e611f6c4